Navigation Links
Novavax Announces Top Line Results of Phase IIa Clinical Trial for Its Seasonal Influenza VLP (Trivalent) Vaccine Candidate
Date:12/11/2008

Favorable immunogenicity results for seasonal vaccine program follows positive results from its pandemic influenza vaccine Phase IIa trial in July 2008; plans to initiate a study of the seasonal vaccine in the elderly in 2009

ROCKVILLE, Md., Dec. 11 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) announced today favorable results from a Phase IIa human clinical trial of its seasonal influenza VLP (trivalent) vaccine candidate. The vaccine, which does not include an adjuvant, induced robust hemagglutination inhibition (HAI) responses, which have been shown to correlate with protection against seasonal influenza disease.

The Phase IIa randomized, placebo-controlled clinical trial evaluated the safety and immunogenicity of different doses of Novavax's seasonal influenza VLP vaccine. Specifically, the vaccine was studied in approximately 300 healthy adults between the ages of 18 to 49 years, who received a single injection of either a placebo or an influenza vaccine at doses of 5 mcg, 15 mcg or 30 mcg per strain.

The adverse events that were reported from the trial are similar in type to those reported for other approved influenza vaccines. Adverse events such as fever, chills, joint pain, muscle aches, headaches, and fatigue were reported at a higher frequency among vaccine as compared with placebo recipients. No serious adverse events have been reported to date. Subjects in the study continue to be monitored for safety through 6 months after vaccination.

The vaccine was immunogenic, inducing HAI responses against the vaccine strains and drifted strains. For subjects in the 15 mcg or 30 mcg vaccination groups, seroprotection rates (i.e., percentage of subjects with HAI titers greater than or equal to 40) for the vaccine strains ranged from 95 to 97% for H3N2, 83 to
'/>"/>

SOURCE Novavax, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Novavax CEO to Present at ACUMENBioFins 9th Annual Healthcare Conference
2. Novavax Reports Third Quarter 2007 Financial Results and Progress with Vaccine Development Programs
3. GE Healthcare and Novavax Establish Collaboration To Develop and Market Pandemic Influenza Solution
4. Novavax Announces Preclinical Results for Seasonal Influenza Vaccine Program
5. Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program
6. Novavax Reports Fourth Quarter and 2007 Year-End Financial Results
7. Novavax Reports Positive Results from Preclinical Studies of its VLP-based Trivalent Seasonal Influenza Vaccine Candidate
8. Novavax Completes Enrollment in Phase I/IIa Pandemic Influenza Vaccine Clinical Trial
9. Novavax Announces Proprietary Method to Create SARS Vaccine and Renewal of NIH Funding for SARS Vaccine Development
10. Novavax to Present Phase I/IIa Trial Data Results in an Investor Conference Call on August 26, 2008
11. Novavax Announces Favorable Results from Phase I/IIa Pandemic Influenza Vaccine Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... EMERYVILLE, Calif. , June 19, 2013 /PRNewswire/ ... performance management solutions, introduced the next-generation of its ... solution, which allows health plans to provide their ... their populations, health factors, medical and prescription drug ... (Logo: http://photos.prnewswire.com/prnh/20100621/SF23660LOGO ) ...
(Date:6/19/2013)... June 19, 2013  It may seem like an odd ... breast cancer. But these were two of the most talked ... Annual Meeting & Expo that just convened in ... this focus by some of the top internal medicine experts ... with new research that can not only save lives, but ...
(Date:6/18/2013)... NEW YORK , June 18, 2013  Intercept ... stage biopharmaceutical company focused on the development and commercialization ... diseases, today announced the pricing of an underwritten public ... a public offering price of $33.01 per share.  In ... to purchase up to an additional 259,500 shares of ...
Breaking Medicine Technology:MedeAnalytics Introduces Next-Generation Employer Group and Individual Business Analytics Solution 2"Miracle" Breast Cancer Drug and "Youth Hormone" Pill Steal Show at Prestigious Endocrine Society Conference 2"Miracle" Breast Cancer Drug and "Youth Hormone" Pill Steal Show at Prestigious Endocrine Society Conference 3"Miracle" Breast Cancer Drug and "Youth Hormone" Pill Steal Show at Prestigious Endocrine Society Conference 4Intercept Pharmaceuticals Announces Pricing of Public Offering of Common Stock 2
... Teikoku Pharma USA, Inc., ("TPU") is pleased to announce ... ("Verde"), a company aimed at developing environmentally responsible solutions ... founded by former executives of TPU and Travanti Pharma, ... products, which are designed to adsorb and inactivate the ...
... provider of the industry,s only four dimensional health information ... in the upcoming joint New Jersey and Delaware Valley ... Demonstration. MobileMD will collaborate with state ... real-time demonstration of secure exchange of health information across ...
Cached Medicine Technology:Updated: Teikoku Pharma USA, Inc. and Verde Environmental Technologies, Inc. Announce Licensing Agreement for Pharmaceutical Disposal Technology 2MobileMD Participates in NJ-DV HIMSS Conference, Interoperability Demo 2
(Date:6/19/2013)... June 19, 2013 The deadline ... is this Friday, June 21 at midnight ET. ... programs and innovative people who’ve raised the bar ... visit http://www.minonline.com/ima . , Any consumer and ... title is eligible to enter. Additionally, advertising agencies ...
(Date:6/19/2013)... Utah (PRWEB) June 19, 2013 Today, ... Wisconsin Health Insurance Exchange . Zane Benefits, which provides ... benefits, is the leader in defined contribution ... to Zane Benefits’ website, as part of the Affordable ... small businesses will become available through new state health ...
(Date:6/19/2013)... Lawrence, KS (PRWEB) June 19, 2013 ... photographs is common with today’s computer software, it creates ... a form of misconduct. As an already published case ... of photo manipulation. , The Journal of Parasitology ... image manipulation in a 2004 article published in ...
(Date:6/19/2013)... results of three important studies have been published in ... of the Congress of Neurological Surgeons . ... Wilkins , a part of Wolters Kluwer Health ... using artificial neural networks (ANNs) may improve the ability ... Another study in the June Neurosurgery supports ...
(Date:6/19/2013)... 19, 2013) In early April, senior leaders from ... Hartford, Connecticut, to discuss one question: how can first ... , The preliminary results of this discussion are ... Events: The Hartford Consensus ," a concept paper published ... Journal of Trauma and Acute Care Surgery , ...
Breaking Medicine News(10 mins):Health News:Entry Deadline for min’s Integrated Marketing Awards Is This Friday, June 21 2Health News:Zane Benefits Publishes New Information on the Wisconsin Health Insurance Exchange 2Health News:Zane Benefits Publishes New Information on the Wisconsin Health Insurance Exchange 3Health News:Altered Photo in Journal Article Illustrates the Need for Manipulation Guidelines 2Health News:Neurosurgery publishes findings of 3 important studies in June issue 2Health News:Neurosurgery publishes findings of 3 important studies in June issue 3Health News:Hartford consensus aims to improve survival after mass shootings 2
... 2009 Laboratory market projections.NEWARK, N.J., April 14 ... G-2 Reports indicates that the clinical diagnostic lab ... by 2017. An increase in genetic testing, ... expanded access to healthcare are among the key ...
... Maine, April 14 IDEXX Laboratories, Inc. (Nasdaq: ... 2009 first quarter financial results for Friday, April 24, at ... conference call beginning at 9:00 a.m. (eastern) on that day. ... through a link on the IDEXX Web site, ...
... & Spa,Group, Inc. (OTC Bulletin Board: SOKF), a leading operator ... CEO Liu, Tong, CFO Yu, Xia,and corporate secretary Mu, Yan ... earnings results at 9 am EDT on Thursday,April 16, 2009. ... * US/Canada Toll Free Dial-in #: (866) 811 - 8933, ...
... related blindness by almost 35%, study suggests, , , TUESDAY, ... age-related macular degeneration is on the increase, newer treatments ... disease by about 35 percent, new estimates suggest. , ... Disease Control and Prevention, researchers report that as many ...
... Six New Board of Directors Members Also Appointed and ... Bruce R. Korf, MD, PhD, FACMG, of Birmingham, AL ... Medical Genetics (ACMG), the national professional organization for medical ... President Joe Leigh Simpson, MD, FACMG, of Miami, FL ...
... April 14 Continuing a nine-year tradition of putting ... Lines (NYSE: DAL ) employees today presented ... gift of more than 1,250 handmade quilts. Each quilt, ... airline employees and other volunteers on their own time.(Logo: ...
Cached Medicine News:Health News:Clinical Diagnostic Lab Testing Market to Grow Over 90% through 2017 2Health News:Clinical Diagnostic Lab Testing Market to Grow Over 90% through 2017 3Health News:SOKO Fitness & Spa Group, Inc. to hold 2009 Q3 Earnings Call on Apr. 16 2Health News:Nearly 18 Million Will Have Macular Degeneration by 2050 2Health News:Nearly 18 Million Will Have Macular Degeneration by 2050 3Health News:Bruce R. Korf, MD, PhD is Named President of the American College of Medical Genetics 2Health News:Bruce R. Korf, MD, PhD is Named President of the American College of Medical Genetics 3Health News:Delta Employees Blanket Salt Lake City Medical Center With Warm Gifts 2
Innotrac Aio! immunoanalyzers are specially designed to exploit the benefits of Innotrac Diagnostics' exclusive dry chemistry and non-enhancement time-resolved fluorometry....
... Synchron LXi 725 clinical system combines ... accurate immunoassay testing capabilities, innovative data ... a single platform. After tests are ... for optimal quality assurance. If reflex ...
... Access immunoassay system is ... benchtop analyzer that performs ... with panels that include ... infectious disease, blood virus, ...
...
Medicine Products: